Table 3.
Co-occurring biomarkers and molecular characteristics
| Cohort 1: NTRK fusion (n = 29) | Cohort 2 (non-matched): NTRK wild-type (n = 12,349) | Cohort 2 (matched): NTRK wild-type (n = 107) | |
|---|---|---|---|
| Co-occurring biomarkers,a n (%) | |||
| TMB status | |||
| High (≥20 mut/mB) | 6 (20.7) | 654 (5.3) | 3 (2.8) |
| Medium (<20, ≥5.5 mut/mB) | 3 (10.3) | 3223 (26.1) | 16 (15.0) |
| MSI-high | 3/17b (17.6) | 93/7902b (1.2) | 1/59b (1.7) |
| ALK rearrangement | 0 | 159 (1.3) | 3 (2.8) |
| BRAF alteration | 1 (3.5) | 812 (6.6) | 8 (7.5) |
| ERBB2 amplification | 0 | 468 (3.8) | 2 (1.9) |
| EGFR alteration | 1 (3.5) | 956 (7.7) | 6 (5.6) |
| ROS1 alteration | 0 | 90 (0.7) | 0 |
| KRAS alteration | 3 (10.3)c | 4811 (39.0) | 25 (23.4) |
MSI microsatellite instability, NTRK neurotrophic tyrosine receptor kinase, TMB tumor mutation burden
aVariants of “known” or “likely” functional status were included, “ambiguous” and “unknown” were excluded
bMSI status missing for 12 patients in Cohort 1, 4447 patients in Cohort 2 (non-matched), and 48 patients in Cohort 2 (matched)
cOne patient was subsequently reclassified as NTRK rearrangement rather than fusion